Squarepoint
ORKA

Squarepoint’s Oruka Therapeutics ORKA Stock Holding History

Squarepoint’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.2M Sell
24,463
-3,208
-12% -$111K ﹤0.01% 2617
2025
Q4 		$839K Buy
+27,671
New +$771K ﹤0.01% 2757
2025
Q2 		– Sell
-22,022
Closed -$226K – 5187
2025
Q1 		$226K Buy
22,022
+9,847
+81% +$123K ﹤0.01% 3933
2024
Q4 		$236K Buy
+12,175
New +$297K ﹤0.01% 4344

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Squarepoint's ORKA Position: Q1 2026 in Review

Squarepoint reduced its Oruka Therapeutics (ORKA) stake by 12% in Q1 2026, selling an estimated $111K and leaving 24,463 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2617.

Squarepoint first reported a position in ORKA in Q4 2024 and has held it in 4 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Squarepoint held 24,463 shares of Oruka Therapeutics worth $1.2M as of Q1 2026.
  • Squarepoint sold 3,208 Oruka Therapeutics shares in Q1 2026, an estimated $111K.
  • Oruka Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2617 holding.
  • Squarepoint first reported a position in Oruka Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.